New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C

EP. 1: Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

March 10th 2021

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

EP. 2: Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

March 10th 2021

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

EP. 3: Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer

March 17th 2021

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.

EP. 4: Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer

March 18th 2021

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

EP. 5: Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

March 18th 2021

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.

EP. 6: Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer

March 22nd 2021

John Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.

EP. 7: Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

March 24th 2021

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

EP. 8: New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C

April 13th 2021

On February 3, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of lung cancer to participate in a virtual workshop to discuss the emerging treatment landscape of targeted therapies in NSCLC. This article summarizes key data about KRAS G12C as a therapeutic target as well as insights from stakeholder discussions regarding this topic.